Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a highly promising therapeutic agent for cancer treatment due to its ability to selectively target tumor cells for cell death, while has little effect on most of normal cells. However, recent research has found that many cancers including non-small cell lung cancer (NSCLC) display resistance to TRAIL. Therefore, it is important to elucidate the molecular mechanism governing the resistance to TRAIL treatment in tumor cells. In this study, we showed the negative regulation of TRAIL-induced apoptosis by GSK3β in H1299 NSCLC cells, and determined the PKCα isozyme as an upstream regulator of GSK3β that phosphorylates and inactivates GSK3β, thereby sensitizing cancer cells to TRAIL-induced apoptosis. Furthermore, we demonstrated that the anti-apoptotic effect of GSK3β is mediated by NF-κB pathway, while the tripartite motif 21 (TRIM21) was able to inhibit the activation of NF-κB by GSK3β, and leads to the promotion of cell apoptosis. Taken together, our study further delineated the underpinning mechanism of resistance to TRAIL-induced apoptosis in H1299 cells and provided new clues for sensitizing NSCLC cells to TRAIL therapy.
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D r a f t
Introduction TRAIL (Tumor necrosis factor related apoptosis-inducing ligand) belongs to the tumor necrosis factor (TNF) family, and is recognized as the most potential therapeutic agent in the TNF superfamily due to its ability to selectively target cancer cells with limited harm toward normal cells (Walczak et al., 1999; Zhuang et al., 2013) . It has been reported that soluble TRAIL and agonistic antibodies against TRAIL receptors are currently applied to clinical trials for cancer therapy (Johnstone et al., 2008; Azijli et al., 2013) . Unexpectedly, almost 50% of human cancer cell lines, such as lung adenocarcinoma cells and a majority of primary cancer cells, become insensitive to TRAIL treatment, reflecting the poor clinical therapeutic efficacy of the treatment (Todaro et al., 2008) . Therefore, the identification of the signaling molecules that are involved in TRAIL-induced cancer cell apoptosis may provide new clues for the development of effective sensitizers for TRAIL therapy (Felber et al., 2007) .
Two signaling pathways, namely the mitochondrial intrinsic apoptotic pathway and the death receptor-mediated extrinsic apoptotic signaling pathway, have been reported to mediate apoptosis in the majority of cells. TRAIL induces cancer cell death mainly through activating the death receptor signaling pathway (Wiley et al., 1995; Kischkel et al., 2000) . Upon the binding of TRAIL to its receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5), TRAIL triggers oligomerization of its receptors and subsequently recruits cytoplasmic proteins FADD (Fas-associated death domain protein) and procaspase 8 (or procaspase 10), thereby forming the death-inducing signaling complex (DISC) (Peter and Krammer, 2003; Johnstone et al., 2008) . After the formation of the DISC complex, procaspase 8 can be cleaved and activated by an autocatalytic mechanism, which leads to the subsequent activation of downstream effector caspases (Kaufmann and Hengartner, D r a f t 4 2001; Johnstone et al., 2008) . In addition to the caspases, several others key factors such as glycogen synthase kinase beta (GSK3β) (Liao et al., 2003; Song et al., 2004; Kotliarova et al., 2008; Beurel et al., 2009) , NF-κB (Lin et al., 2000; Zhang and Fang, 2005) , PKC (Harper et al., 2003; Azijli et al., 2013; McCray et al., 2014; Hayashi et al., 2015) , cellular FLICE-inhibitory protein (c-FLIP) (Leverkus et al., 2000; Chen et al., 2011) , and X-linked IAP (XIAP) (Deveraux et al., 1998) have also been demonstrated to be essential for this process.
GSK3β, a member of GSK3 family, was initially identified as an enzyme that is capable of phosphorylating glycogen synthase (Embi et al., 1980) . Recent studies have reported that GSK3β is involved in the regulation of various cellular processes, such as survival, apoptosis, cell mobility, and embryonic development (Sanchez et al., 2003; Luo, 2009) . The phosphorylation of Ser9 of GSK3β inhibits its enzymatic activity (Cross et al., 1995) , while the phosphorylation of Tyr216 of GSK3β enhances its enzymatic activity (Kim et al., 1999) . To date, several kinases such as PKC and Akt have been reported to phosphorylate GSK3β at Ser9 (Cross et al., 1995) . GSK3β is well-known for its bifunctional effects on apoptotic signaling pathways, facilitating the mitochondrial intrinsic apoptotic pathway while blocking the death receptor-induced apoptosis (Beurel and Jope, 2006 ) . Here, we focus on the regulating mechanism of GSK3β involved in the apoptosis induced by TRAIL in human lung adenocarcinoma H1299 cells.
Protein kinase C (PKC), a family of serine/threonine protein kinases, is activated by numerous stimuli and has versatile biological functions including regulating cell proliferation, survival, and apoptosis (Griner and Kazanietz, 2007; Chen et al., 2011; Zhang et al., 2014a) . PKC isozymes can be classified into three subtypes (Spitaler and Cantrell, 2004) : 1) the conventional cPKCs (α, β, γ), activated by diacylglycerol (DAG), calcium, or phosphatidylserine; 2) the novel D r a f t 5 nPKCs (δ, ε, η, θ), activated by DAG and independent on calcium; and 3) the atypical aPKCs (ζ, λ/ι), activated by phosphatidylserine and independent on calcium and DAG. Different PKC isozymes have diverse cellular effects, such as pro-apoptosis or anti-apoptosis, depending on different stimuli and cell types (Gavrielides et al., 2004; Martelli et al., 2004) . For example, the activation of the novel PKCδ, PKCε, and PKCη promotes cell survival and inhibits TRAIL-induced apoptosis in melanoma and breast cancer cells (Azijli et al., 2013) , whereas PKCα has been suggested to increase the expression of TRAIL-R2, thereby contributing to the sensitization of TRAIL-induced apoptosis in non-small cell lung cancer (NSCLC) cells (Chen et al., 2007; Azijli et al., 2013) . Nevertheless, the specific role of PKCα isozyme and its downstream signaling pathway in TRAIL-induced apoptosis in H1299 cells is largely unknown. NF-κB has been shown to be an important transcription factor in the regulation of the resistance to TRAIL in cancer cells (Hoeflich et al., 2000; Aydin et al., 2010; Wang et al., 2014; Zhang et al., 2014b) . Moreover, its transcriptional activity can be regulated by GSK3β (Aydin et al., 2010; Zhang et al., 2014b) on one hand, and on the other hand, by the tripartite motif (TRIM) family members (Tomar and Singh, 2015) . TRIM family is defined by the existence of an N-terminal tripartite motif including a RING domain, one or two B-boxes and a Coiled-coil region (Micale et al., 2012) . It contains more than 70 members and mediates a diversity of biological processes (Tomar and Singh, 2015) . Particularly, TRIM21, one member of TRIM family, has been reported to suppress the transcriptional activity of NF-κB (Niida et al., 2010) . However, the role of TRIM21 in the regulation of TRAIL-induced apoptosis, as well as its relationship with GSK3β in such process is unknown.
In the present study, we confirmed the protective role of GSK3β in TRAIL-induced D r a f t 6 apoptosis in H1299 NSCLC cells, and demonstrated PKCα is the specific isozyme capable of phosphorylating and inactivating GSK3β, which enhances the apoptosis induced by TRAIL. Then, we showed that TRIM21 acts downstream of GSK3β in the signaling cascade to negatively regulate NF-κB activation during the cell apoptosis.
Materials and methods

Cell culture
Lung adenocarcinoma H1299 cells (Institute of life science Chinese Academy of Sciences, Shanghai, China) were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco BRL, Grand island, NY) supplemented with 10% fetal bovine serum (PAN-Biotech, Germany), in a humidified atmosphere containing 5% CO 2 at 37°C.
MTT assays
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, Beyotime Biotechnology, China) assays were used to evaluated the effects of TRAIL treatment on cell viability. H1299 cells (4×10 3 cells/well) were seeded into 96-well plate (TCP011096, JET, Guangzhou, China) and incubated overnight. Then, the cells were treated with TRAIL (20 ng/ml) for different durations. Lastly, the cells were cultured with MTT solution (final concentration is 20 µg/ml) for 4 h at 37°C incubator and the generated formazan crystals were dissolved in 150 µl DMSO/well. A spectrophotometric microplate reader (ELX800, BioTek Instrument, USA) was used to measure the absorbance of formazan crystals at 570 nm, and cellular viability corresponding to absorbance value was analyzed.
In vitro phosphorylation assay
GST-GSK3β fusion protein was expressed and purified as described previously (Gao et al., 2013; Gao et al., 2014 
Small interfering RNAs (siRNAs) assays
SiRNAs target against GSK3β or PKCα were synthetized in GenePharma (Shanghai, China).
The sense strand sequence of siRNA target GSK3β is:
5'-AAGUAAUCCACCUCUGGCUACTT-3'. The sense strand sequences of siRNA target PKCα is: 5'-AAGAGGTGCCATGAATTTGTT-3' (Cameron et al., 2008) . The sequence of 5'-UUCUCCGAACGUGUCACGUTT-3' was used as negative control (NC). These siRNAs (100nM) were transfected into H1299 cells using Lipofectamin 2000 according to the manufacturer's instruction (Invitrogen). The interfered cells were harvested 48 h post-transfection.
Plasmid transfection and western blot analysis
Plasmids of Flag-GSK3β1, mCherry-GSK3β1 and mCherry-GSK3β1 S9A mutant were constructed previously (Gao et al., 2014 Blots were probed with antibodies against Flag (A2220, Sigma), HA (H9658, Sigma), GSK3β, phospho-GSK3β (Ser9), Cleaved Caspase 3 (Cell Signaling Technology), GAPDH (ZSGB-BIO, China), mCherry (Abbkine, USA), and p-NF-kB p65 (Ser536) (Santa Cruz) following the standard protocol (Gao et al., 2013; Gao et al., 2014; Gao et al., 2015) . The quantitative analysis of immunoblot results was carried out using Image J software. 
Luciferase Assay
To detect the transcriptional activity of NF-κB, NF-κB luciferase reporter plasmid p-NF-κB-TA-Luc (kindly provided by Prof. Xu Jiake) was used as described previously (Gao et al., 2014) . Briefly, after transfection of p-NF-κB-TA-Luc plasmid for 12 h in a 6-well plate, other indicated plasmids or siRNA were co-transfected into H1299 cells for another 4 h and the cells were re-suspended in culture medium and reseeded into a 24-well plate at a density of 2×10 5 cells/well. Cells were cultured during 30 hours, then treated with TRAIL (20 ng/ml) or LiCl (20 mM) for 8 more hours. Finally, cells were harvested and prepared for luciferase assays as described previously (Gao et al., 2014) .
Statistics analysis
Statistical analysis using Student's t-test was performed and the statistical significance was defined as p<0.05.
D r a f t
Results
GSK3β β β β inhibits TRAIL-induced apoptosis in H1299 cells
In order to investigate the functional relationship among GSK3β, NF-κB and TRIM21 in TRAIL-induced apoptosis in H1299 cells, we have firstly set up a cell model by confirming the cytotoxic effect of TRAIL for H1299 cells, and the role of GSK3β in TRAIL-induced apoptosis.
Consistent with previously report, our result showed that TRAIL indeed time-dependently inhibited the cell viability of H1299 cells (Fig. 1A ). This result was further confirmed by Western blotting showing the increased level of the cleaved caspase 3, a marker for cell apoptosis ( Taken together, these results suggested that GSK3β negatively regulated TRAIL-induced H1299 cell apoptosis.
PKCα enhanced TRAIL-induced H1299 cell apoptosis via phosphorylating GSK3β β β β
PKC is known to be able to phosphorylate GSK3β at Ser9 residue (Cross et al., 1995) .
Meanwhile, the Ser9 phosphorylation of GSK3β is involved in the process of TRAIL stimulation (Cross et al., 1995; Azijli et al., 2013) . So we asked if the PKC-GSK3β signaling pathway could be effective in the process of TRAIL-induced apoptosis in H1299 cells. To this end, we used LiCl is a widely used GSK3β inhibitor which increases its Ser 9 phosphorylation level by interfering its PP1 (protein phosphatase-1)-mediated dephosphorylation (Zhang et al., 2003) . The combination of LiCl with the PKC inhibitor Gö6983 would allow us to access the importance of GSK3β as the effector of PKC in TRAIL-induced apoptosis. As shown in Fig. 2A , upon the treatment of TRAIL, the cleavage of caspase 3 was increased, and LiCl further increased the cleavage of caspase 3, accompanied with the increased Ser9 phosphorylation of GSK3β.
Interestingly, Gö6983 significantly reduced GSK3β Ser9 phosphorylation, but had little effect on TRAIL-induced caspase 3 cleavages regardless of LiCl treatment, although a slight increase of cleaved caspase 3 level could be observed with Gö6983 plus LiCl compared with Gö6983 only.
This might be explained by the fact that Gö6983, as a pan-inhibitor of PKC isozymes, could have simultaneously blocked the pro-survival and pro-apoptosis PKC subtypes, resulting in the mutual offset between the opposing effects. In order to verify this hypothesis, we sought to determine the specific role of the PKCα isozyme in the Ser9 phosphorylation of GSK3β during the TRAIL-induced apoptosis. As shown in Fig. 2B , we found that Flag-PKCα overexpression dramatically elevated the Ser9 phosphorylation of GSK3β in a dose-dependent manner, which is, more interestingly, echoed by the similar dose-dependent increase of caspase 3 cleavage. In contrast, knockdown of PKCα decreased Ser9 phosphorylation of GSK3β, with the compromise of the apoptotic efficiency upon TRAIL treatment (Fig. 2C) . These results suggested that PKCα exerts a pro-apoptotic role in TRAIL-induced apoptosis through Ser9 phosphorylation of GSK3β in H1299 cells. Subsequently, we confirmed the Ser9 phosphorylation of GSK3β by PKCα kinase in vitro using purified PKCα kinase, PP1 phosphatase, and GST-GSK3β. As shown in Fig. 2D , the D r a f t 13 incubation of purified GST-GSK3β fusion protein with the active PKCα significantly increased its Ser9 phosphorylation level. This effect could be counterweighed by PP1 phosphatase (Fig. 2D ).
GSK3β β β β is an effector of PKCα in TRAIL-induced H1299 cell apoptosis
Given that GSK3β could be phosphorylated by PKCα in TRAIL-induced H1299 cell apoptosis, we further determine the importance of GSK3β as the downstream effector of PKCα.
To this end, we combined the overexpression or knockdown of PKCα with that of GSK3β in the cells treated or not with TRAIL, and evaluated the degree of apoptosis by Western blotting using anti-cleaved caspase 3 antibody. After knockdown of PKCα, cleaved caspase 3 significantly reduced, and simultaneous knockdown of GSK3β blocked this reduction (Fig. 3A) . More convincingly, while PKCα overexpression was capable of reducing the anti-apoptotic effect of GSK3β overexpression (Fig. 3B) , it seems to be devoid of such capacity on GSK3β-S9A (taken into account the varying expression levels of mCherry-GSK (WT and S9A mutant) and PKCα), the phospho-defective mutant of GSK3β (Fig. 3C ). This suggests that PKCα promotes TRAIL-induced apoptosis perhaps through Ser9 phosphorylation of GSK3β.
Upregulation of NF-κB pathway by GSK3β β β β in TRAIL-induced H1299 cell apoptosis
Previous studies have demonstrated that NF-κB is a critical transcription factor that mediated TRAIL-induced apoptosis in various cells (Hoeflich et al., 2000; Aydin et al., 2010; Zhang et al., 2014b) . As shown in Fig. 4A , we also found that NF-κB inhibitor BAY 11-7082 remarkably sensitized TRAIL-induced apoptosis, as judged by increase of the cleaved caspase 3 level, which peaked when BAY 11-7082 was used at 10 µM. The inhibitory effect of BAY 11-7082 (10 µM, 8 D r a f t 14 hours) on the activity of NF-κB was confirmed in Fig. S1 and there is no off target effect of BAY 11-7082 on GSK3β (Anastassiadis et al., 2011) . We then attempted to confirm the regulation of NF-κB pathway by GSK3β in our cellular model. As shown in Fig. 4B and 4C, without TRAIL treatment, neither the inhibition of GSK3β by LiCl nor its knockdown had obvious effect on the NF-κB transcriptional activity. Induction of H1299 cells by TRAIL exerted an inhibitory effect on NF-κB pathway, which was further strengthened by LiCl treatment or knockdown of GSK3β (Fig.   4B , C). This result confirmed the inhibition of NF-κB pathway by inhibiting or knocking down of GSK3β in the process of TRAIL-induced apoptosis. In support with this, treatment of BAY 11-7082 compromised the reduction of cleaved caspase 3 induced by Flag-GSK3β under TRAIL treatment (Fig. 4D) . These results collectively suggest that GSK3β positively regulates NF-κB pathway in TRAIL-induced H1299 cell apoptosis.
TRIM21 counteracts the promotion of NF-κB pathway by GSK3β β β β under TRAIL treatment
It has been reported that TRIM21 suppressed the transcriptional activity of NF-κB (Niida et al., 2010) , but no study concerning its possible role in TRAIL-induced apoptosis has yet been reported. In order to address this issue, we have firstly determined the effect of TRAIL on the expression of TRIM21. As shown in Fig. 5A , no obvious variation of TRIM21 expression could be detected upon TRAIL treatment. Next, we assessed the effect of TRIM21 overexpression and knockdown on TRAIL induced-apoptosis. As shown in Fig. 5B , overexpression of TRIM21 augmented the level of cleaved caspase-3, and consistently, its knockdown decreased the level of the latter, confirming the pro-apoptosis role of this protein (Fig. 5C ). Interestingly, TRIM21
overexpression significantly inhibited NF-κB activation regardless of TRAIL treatment (Fig. 5D ).
Moreover, the stimulation of NF-κB activity by GSK3β overexpression under TRAIL treatment was remarkably inhibited by the co-overexpression of TRIM21, further supported by the Western blotting analysis of the cleaved caspase 3 level which was reduced by GSK3β overexpression but re-ascend when TRIM21 was also co-overexpressed (Fig. 5E ). Taken together, these results suggest that TRIM21 is a regulator of TRAIL-induced cell apoptosis whose function is possibly linked to the anti-apoptotic GSK3β. GSK3β-mediated activation of NF-κB pathway, which suppressed cell apoptosis.
Various isozymes of PKC have been reported to be involved in the regulation of TRAIL-induced tumor cell apoptosis. In melanoma cells and breast cancer cells, the activation of the novel PKC (δ, ε) led to TRAIL resistance (Gillespie et al., 2005; Shankar et al., 2008; Azijli et al., 2013) . Novel PKCδ and η isozymes have also been identified as key targets for antagonizing TRAIL's cytotoxic activity (Sonnemann et al., 2004; Hayashi et al., 2015) . In addition, inhibition of novel PKC using NPC 15437 significantly augmented sensitivity of A549 cells to TRAIL, however, inhibition of the conventional PKC using Gö6976 did not increase its sensitivity to TRAIL (Felber et al., 2007) . The anti-apoptotic mechanism of PKC involves activation of pro-survival Akt and reduction of p53 (Shankar et al., 2008) , inhibition of recruitment of FADD D r a f t and caspase-8, and the latter leads to the disruption of DISC formation (Harper et al., 2003) . On the contrary, the activation of conventional PKC (α, β, γ) by PMA (PKC activator) or bryostatin-1 sensitizes TRAIL-induced apoptosis through up-regulating the expression of Bad and TRAIL receptors (Farrow et al., 2002) . In NSCLC cells, the authors suggest that PKCα promotes TRAIL-R2 expression and contributed to the sensitization of TRAIL-induced cytotoxicity by quercetin (Chen et al., 2007; Azijli et al., 2013) . In agreement with these reports, our study has demonstrated the role of PKCα as an apoptosis promoter on TRAIL-induced apoptosis in NSCLC H1299 cells (Fig. 2) , by phosphorylating and inactivating GSK3β. Our results further clarified the role of PKCα and the related mechanism in TRAIL's cytotoxicity. cleavage while GSK3β knockdown augmented caspase 3 cleavage (Fig. 1) . In addition, our results demonstrated that NF-κB is the downstream effector which is responsible for the anti-apoptotic role of GSK3β under TRAIL treatment in H1299 cells (Fig. 4) , reconfirming the previous studies Recent review has reported that TRIMs act as E3 ligases and are extensively involved in the regulation of NF-κB pathway at different levels (Tomar and Singh, 2015) . TRIM21 is shown to induce the mono-ubiquitination and degradation of IKKβ, leading to the suppression of NF-κB activity (Wada et al., 2009; Niida et al., 2010) . In agreement with this conclusion, our result showed that overexpression of TRIM21 dramatically reduced NF-κB transcriptional activity under TRAIL treatment (Fig. 5D) . Furthermore, TRIM21 negatively regulated the augmented activation of NF-κB induced by GSK3β overexpression (Fig. 5E ). Thus, TRIM21 counteracted the protective effect of GSK3β against TRAIL's cytotoxicity and significantly promoted TRAIL-induced apoptosis. Taking into account the previous studies showing that these two proteins are both capable to act on IKK in NF-κB pathway, as cited above, our results may suggest that the functions of GSK3β and TRIM21 in the regulation of NF-κB pathway might be linked by a common molecular mechanism which needs further investigation in the future.
In conclusion, our study delineates the PKCα/GSK3β/NF-κB axis in H1299 cells under the treatment of TRAIL in which PKCα functions as an apoptosis promoter through phosphorylating and inactivating the pro-survival GSK3β. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., et al. 1999 . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 
